MVD-1 (SANA)
Obesity
Key Facts
About Eolo Pharma
Eolo Pharma is developing first-in-class oral thermogenic drugs that work by increasing resting energy expenditure, a novel mechanism distinct from current appetite-suppressing treatments. Its lead program, SANA/MVD-1, is positioned as a potential monotherapy or combination agent for obesity and its comorbidities, backed by peer-reviewed research published in journals like Nature Metabolism. The company is privately held, has a pipeline of 60 novel chemical entities, and is led by a team with expertise in metabolic science and drug development. Eolo's strategy targets the massive obesity market by offering a scientifically differentiated approach to reset metabolic health.
View full company profileAbout Eolo Pharma
Eolo Pharma is developing first-in-class oral thermogenic drugs that work by increasing resting energy expenditure, a novel mechanism distinct from current appetite-suppressing treatments. Its lead program, SANA/MVD-1, is positioned as a potential monotherapy or combination agent for obesity and its comorbidities, backed by peer-reviewed research published in journals like Nature Metabolism. The company is privately held, has a pipeline of 60 novel chemical entities, and is led by a team with expertise in metabolic science and drug development. Eolo's strategy targets the massive obesity market by offering a scientifically differentiated approach to reset metabolic health.
View full company profileAbout Eolo Pharma
Eolo Pharma is developing first-in-class oral thermogenic drugs that work by increasing resting energy expenditure, a novel mechanism distinct from current appetite-suppressing treatments. Its lead program, SANA/MVD-1, is positioned as a potential monotherapy or combination agent for obesity and its comorbidities, backed by peer-reviewed research published in journals like Nature Metabolism. The company is privately held, has a pipeline of 60 novel chemical entities, and is led by a team with expertise in metabolic science and drug development. Eolo's strategy targets the massive obesity market by offering a scientifically differentiated approach to reset metabolic health.
View full company profileAbout Eolo Pharma
Eolo Pharma is developing first-in-class oral thermogenic drugs that work by increasing resting energy expenditure, a novel mechanism distinct from current appetite-suppressing treatments. Its lead program, SANA/MVD-1, is positioned as a potential monotherapy or combination agent for obesity and its comorbidities, backed by peer-reviewed research published in journals like Nature Metabolism. The company is privately held, has a pipeline of 60 novel chemical entities, and is led by a team with expertise in metabolic science and drug development. Eolo's strategy targets the massive obesity market by offering a scientifically differentiated approach to reset metabolic health.
View full company profileOther Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |
| Undisclosed siRNA Programs | Moonwalk Biosciences | Pre-clinical |
| VIAL-INHBE (siRNA) | VIAL Dermatology CRO | Phase 1 |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |